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For a new tuberculin skin test (TST) to be considered
useful, it must meet several requirements including
safety, a readable skin response, affordability, a high pre-
dictive value, and it cannot easily sensitize, depend on
patient characteristics, nor depend on the Mycobacter-
ium tuberculosis isolate. After review of previously
conducted animal model studies, we designed a double-
blind randomized Phase 1 study comparing recombinant
dimer ESAT-6 (rdESAT-6, Statens Serum Institut,
Copenhagen, Denmark) to tuberculin as a skin test
reagent in the diagnosis of TB. The goals of the study
were to assess the safety of an intradermal method of
administering the test and to determine the appropriate
human dose. The study compared the administration of
2.0 TU PPD (standard dose of RT 23) to four doses of
rdESAT-6 (0.01, 0.1, 1, and 10μg). The protocol also
called for intra-subject randomization of the left and
right forearm. Participants were enrolled in eight differ-
ent groups. Four groups comprised five healthy controls
each for the purpose of testing safety and sensitization
issues. The other four groups comprised patients who
had been treated for TB in order to determine safety
and optimal dose. Several exclusion criteria were
applied, including individuals who had received a TST
test within the past year or had a known immune defi-
ciency. During the 28-day trial, the guidelines called for
2 hours of close observation after administering the test
on Day 0; clinical parameters, photography on Days 1 to
4 with quantiFERON testing of control subjects on Day
2 and lab and urine tests on Day 4; diary keeping on
Days 5 to 28 with physical exam, lab and urine tests on
Day 28 and quantiFERON testing of control groups.
In control groups, all four dosages of rdESAT-6 were
administered with no serious side effects; transient
redness occurred at 24 hours at the 10 μg dose; and no
indication of sensitization was measured in vitro. In the
treated TB group, only doses of 0.01 and 0.1 of rdESAT-
6 were well-tolerated; equivalent responses to PPD and
0.1 μg rdESAT-6 were observed. Participants reported
significant local side effects at 1 μg of rdESAT-6. Results
indicate that the new skin test is safe, produced a read-
able skin test response, did not easily sensitize, and is
robust in all practical aspects. Further studies must be
conducted on subjects ranging from individuals with
active and latent TB, children, pregnant women, and
patients who are immunocompromised.
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